Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eur J Clin Pharmacol ; 69(3): 309-17, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22890586

RESUMO

PURPOSE: Bioavailability of clopidogrel in the form of crushed tablets administered via nasogastric tube (NGT) has not been established in patients after cardiopulmonary resuscitation. Therefore, we performed a study comparing pharmacokinetic and pharmacodynamic response to high loading dose of clopidogrel in critically ill patients after cardiopulmonary resuscitation (CPR) with patients scheduled for elective coronary angiography with stent implantation. METHODS: In the NGT group (nine patients, after cardiopulmonary resuscitation, mechanically ventilated, therapeutic hypothermia), clopidogrel was administered in the form of crushed tablets via NGT. Ten patients undergoing elective coronary artery stenting took clopidogrel per os (po) in the form of intact tablets. Pharmacokinetics of clopidogrel was measured with high-performance liquid chromatography (HPLC) before and at 0.5, 1, 6, 12, 24 h after administration of a loading dose of 600 mg. In five patients in each group, antiplatelet effect was measured with thrombelastography (TEG; Platelet Mapping) before and 24 h after administration. RESULTS: The carboxylic acid metabolite of clopidogrel was detected in all patients in the po group. In eight patients, the maximum concentration was measured in the range of 0.5-1 h after the initial dose. In four patients in the of NGT group, the carboxylic acid metabolite of clopidogrel was undetectable and in the remaining patients was significantly delayed (peak values at 12 h). All patients in the po group reached clinically relevant (>50 %) inhibition of thrombocyte adenosine diphosphate (ADP) receptor after 24 h compared with only two in the NGT group (p = 0.012). There was a close correlation between peak of inactive clopidogrel metabolite plasmatic concentration and inhibition of the ADP receptor (r = 0.79; p < 0.001). CONCLUSION: The bioavailability of clopidogrel in critically ill patients after cardiopulmonary resuscitation is significantly impaired compared with stable patients. Therefore, other drugs, preferentially administered intravenously, should be considered.


Assuntos
Plaquetas/efeitos dos fármacos , Reanimação Cardiopulmonar , Intervenção Coronária Percutânea , Inibidores da Agregação Plaquetária/farmacocinética , Antagonistas do Receptor Purinérgico P2/farmacocinética , Ticlopidina/análogos & derivados , Administração Oral , Idoso , Idoso de 80 Anos ou mais , Disponibilidade Biológica , Plaquetas/metabolismo , Cromatografia Líquida de Alta Pressão , Clopidogrel , Estado Terminal , Feminino , Humanos , Hipotermia Induzida , Intubação Gastrointestinal , Masculino , Pessoa de Meia-Idade , Intervenção Coronária Percutânea/instrumentação , Inibidores da Agregação Plaquetária/administração & dosagem , Inibidores da Agregação Plaquetária/sangue , Antagonistas do Receptor Purinérgico P2/administração & dosagem , Antagonistas do Receptor Purinérgico P2/sangue , Receptores Purinérgicos P2/efeitos dos fármacos , Receptores Purinérgicos P2/metabolismo , Respiração Artificial , Stents , Comprimidos , Tromboelastografia , Ticlopidina/administração & dosagem , Ticlopidina/sangue , Ticlopidina/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA